Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Sygnis AG. (12/17/15). "Press Release: Sygnis Significantly Expands Its Asian Distribution Network by Signing Three Additional Agreements with PhileKorea and Pharma Tech Korea as Well as Axil Scientific for Singapore". Madrid & Heidelberg.

Region Region Korea, Republic of
Organisations Organisation Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Genetrix (ES) (Group)
  Organisation 2 Philekorea Technology Inc.
Products Product TruePrime™ kit (product series)
  Product 2 SunScript™ One Step RT-PCR Kit
Persons Person de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)
  Person 2 Gabriel, Raimund (MC Services 1999–201101– Founder + CEO)
     


> SYGNIS’ new partners are industry leading distributors focused on molecular biology, protein research, cell biology and diagnostics

> Agreements cover the entire SYGNIS portfolio of powerful tools for next generation sequencing (NGS), single cell analysis (SCA) and liquid biopsies applications


SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed three additional non-exclusive distribution agreements with PhileKorea, Pharma Tech Korea and Axil Scientific for the commercialization of SYGNIS’ proprietary product portfolio in Korea and Singapore and thereby significantly expands its Asian footprint.

With these agreements, SYGNIS grants non-exclusive rights to promote, market and sell all existing as well as future product lines to scientists working in genomics, proteomics and diagnostics in Korea and Singapore. These product lines cover the Company’s revolutionary TruePrimeTM products for primer-free whole genome amplification (WGA) as well as SunScriptTM thermostable reverse transcriptase kits for the translation of RNA into DNA including the newly launched SunScriptTM One Step Reverse Transcriptase (RT)- PCR Kit for parallel transcription and amplification of genomic information.

“We are very pleased about these distribution agreements for our proprietary product portfolio with industry leading partners in the growing life science markets of Korea and Singapore,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “After we successfully announced distributions agreements for the US just two weeks ago, we today were able to significantly expand our footprint in the Asian markets. We are very focused and committed to further building up and expanding our distribution channel program in 2016 in order to make our products widely available.”

Visit our website for additional information on SYGNIS products: http://www.sygnis.com.


About TruePrime™

TruePrimeTM is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrimeTM is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.


About SunScript™

SunScriptTM RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScriptTM Reverse Transcriptase will be available in two versions: SunScriptTM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScriptTM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.


For further information please contact:

SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Genetrix (ES) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top